Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 3, 2013, Pages 663-671

  Jiang, Guan Min ^a,b   Wang, Hong Sheng ^b   Zhang, Fan ^b   Zhang, Kun Shui ^c   Liu, Zong Cai ^b   Fang, Rui ^b   Wang, Hao ^b   Cai, Shao Hui ^d   Du, Jun ^b  

^a THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d JINAN UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transitions; Histone deacetylase inhibitors; Snail; Tumor metastasis; Vimentin

Indexed keywords

BUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; VIMENTIN; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER MORPHOLOGY; CELL INVASION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FIBROBLAST; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR CELL; TUMOR CELL LINE; UBIQUITINATION; UPREGULATION;

BLOTTING, WESTERN; CADHERINS; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOPRECIPITATION; NASOPHARYNGEAL NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; UP-REGULATION; VIMENTIN; WOUND HEALING;

GASTROPODA;

EID: 84871860201     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.12.002     Document Type: Article

References (46)

1. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
2. David G., Alland L., Hong S.H., Wong C.W., DePinho R.A., Dejean A. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 1998, 16:2549-2556.
3. Inokoshi J., Katagiri M., Arima S., Tanaka H., Hayashi M., Kim Y.B., Furumai R., Yoshida M., Horinouchi S., Omura S. Neuronal differentiation of neuro 2a cells by inhibitors of cell cycle progression, trichostatin A and butyrolactone I. Biochem. Biophys. Res. Commun. 1999, 256:372-376.
4. Saunders N., Dicker A., Popa C., Jones S., Dahler A. Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res. 1999, 59:399-404.
5. Huang H., Reed C.P., Zhang J.S., Shridhar V., Wang L., Smith D.I. Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. Cancer Res. 1999, 59:2981-2988.
6. Richon V.M., Sandhoff T.W., Rifkind R.A., Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:10014-10019.
7. Sambucetti L.C., Fischer D.D., Zabludoff S., Kwon P.O., Chamberlin H., Trogani N., Xu H., Cohen D. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 1999, 274:34940-34947.
8. Rasheed W.K., Johnstone R.W., Prince H.M. Histone deacetylase inhibitors in cancer therapy. Expert Opin. Investig. Drugs 2007, 16:659-678.
9. Duvic M., Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin. Investig. Drugs 2007, 16:1111-1120.
10. Blumenschein G.R., Kies M.S., Papadimitrakopoulou V.A., Lu C., Kumar A.J., Ricker J.L., Chiao J.H., Chen C., Frankel S.R. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest. New Drugs 2008, 26:81-87.
11. O'Connor O.A., Heaney M.L., Schwartz L., Richardson S., Willim R., MacGregor-Cortelli B., Curly T., Moskowitz C., Portlock C., Horwitz S., Zelenetz A.D., Frankel S., Richon V., Marks P., Kelly W.K. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 2006, 24:166-173.
12. Jiang G.M., He Y.W., Fang R., Zhang G., Zeng J., Yi Y.M., Zhang S., Bu X.Z., Cai S.H., Du J. Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and post-transcriptional levels. Int. J. Biochem. Cell Biol. 2010, 42:1840-1846.
13. Chung Y.L., Lee Y.H., Yen S.H., Chi K.H. A novel approach for nasopharyngeal carcinoma treatment uses phenylbutyrate as a protein kinase C modulator: implications for radiosensitization and EBV-targeted therapy. Clin. Cancer Res. 2000, 6:1452-1458.
14. Kim Y.H., Park J.W., Lee J.Y., Kwon T.K. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 2004, 25:1813-1820.
15. Decrion-Barthod A.Z., Bosset M., Plissonnier M.L., Marchini A., Nicolier M., Launay S., Pretet J.L., Rommelaere J., Mougin C. Sodium butyrate with UCN-01 has marked antitumour activity against cervical cancer cells. Anticancer Res. 2010, 30:4049-4061.
16. Shook D., Keller R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech. Dev. 2003, 120:1351-1383.
17. Xue C., Plieth D., Venkov C., Xu C., Neilson E.G. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res. 2003, 63:3386-3394.
18. Behrens J., Mareel M.M., Van Roy F.M., Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J. Cell Biol. 1989, 108:2435-2447.
19. Guarino M. Epithelial-to-mesenchymal change of differentiation. From embryogenetic mechanism to pathological patterns. Histol. Histopathol. 1995, 10:171-184.
20. Fuchs I.B., Lichtenegger W., Buehler H., Henrich W., Stein H., Kleine-Tebbe A., Schaller G. The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res. 2002, 22:3415-3419.
21. Kokkinos M.I., Wafai R., Wong M.K., Newgreen D.F., Thompson E.W., Waltham M. Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and in vivo. Cells Tissues Organs 2007, 185:191-203.
22. Zeisberg M., Neilson E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 2009, 119:1429-1437.
23. Zavadil J., Bottinger E.P. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005, 24:5764-5774.
24. Kim K., Lu Z., Hay E.D. Direct evidence for a role of beta-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol. Int. 2002, 26:463-476.
25. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 2005, 17:548-558.
26. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
27. McCoy E.L., Iwanaga R., Jedlicka P., Abbey N.S., Chodosh L.A., Heichman K.A., Welm A.L., Ford H.L. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:2663-2677.
28. Prasad C.P., Rath G., Mathur S., Bhatnagar D., Parshad R., Ralhan R. Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast. BMC Cancer 2009, 9:325.
29. Logullo A.F., Nonogaki S., Pasini F.S., Osorio C.A., Soares F.A., Brentani M.M. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression. Oncol. Rep. 2010, 23:313-320.
30. Zhu X.F., Liu Z.C., Xie B.F., Li Z.M., Feng G.K., Yang D., Zeng Y.X. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett. 2001, 169:27-32.
31. Barbera M.J., Puig I., Dominguez D., Julien-Grille S., Guaita-Esteruelas S., Peiro S., Baulida J., Franci C., Dedhar S., Larue L., Garcia de Herreros A. Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene 2004, 23:7345-7354.
32. Bachelder R.E., Yoon S.O., Franci C., de Herreros A.G., Mercurio A.M. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J. Cell Biol. 2005, 168:29-33.
33. Li H., Wu X. Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. Biochem. Biophys. Res. Commun. 2004, 324:860-867.
34. Byrd J.C., Marcucci G., Parthun M.R., Xiao J.J., Klisovic R.B., Moran M., Lin T.S., Liu S., Sklenar A.R., Davis M.E., Lucas D.M., Fischer B., Shank R., Tejaswi S.L., Binkley P., Wright J., Chan K.K., Grever M.R. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105:959-967.
35. Reid T., Valone F., Lipera W., Irwin D., Paroly W., Natale R., Sreedharan S., Keer H., Lum B., Scappaticci F., Bhatnagar A. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 2004, 45:381-386.
36. Stadler W.M., Margolin K., Ferber S., McCulloch W., Thompson J.A. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer 2006, 5:57-60.
37. Ellis L., Pili R. Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel, Switzerland) 2010, 3:2411-2469.
38. Sadoul K., Boyault C., Pabion M., Khochbin S. Regulation of protein turnover by acetyltransferases and deacetylases. Biochimie 2008, 90:306-312.
39. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., Yoo M.A., Song E.J., Lee K.J., Kim K.W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002, 111:709-720.
40. Hernandez-Hernandez A., Ray P., Litos G., Ciro M., Ottolenghi S., Beug H., Boyes J. Acetylation and MAPK phosphorylation cooperate to regulate the degradation of active GATA-1. EMBO J. 2006, 25:3264-3274.
41. Leduc C., Claverie P., Eymin B., Col E., Khochbin S., Brambilla E., Gazzeri S. p14ARF promotes RB accumulation through inhibition of its Tip60-dependent acetylation. Oncogene 2006, 25:4147-4154.
42. Tang Y., Zhao W., Chen Y., Zhao Y., Gu W. Acetylation is indispensable for p53 activation. Cell 2008, 133:612-626.
43. Simonsson M., Heldin C.H., Ericsson J., Gronroos E. The balance between acetylation and deacetylation controls Smad7 stability. J. Biol. Chem. 2005, 280:21797-21803.
44. Jin Y.H., Jeon E.J., Li Q.L., Lee Y.H., Choi J.K., Kim W.J., Lee K.Y., Bae S.C. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J. Biol. Chem. 2004, 279:29409-29417.
45. Vervoorts J., Luscher-Firzlaff J.M., Rottmann S., Lilischkis R., Walsemann G., Dohmann K., Austen M., Luscher B. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep. 2003, 4:484-490.
46. De Craene B., van Roy F., Berx G. Unraveling signalling cascades for the Snail family of transcription factors. Cell. Signal. 2005, 17:535-547.